Oxford University to Start COVID-19 Vaccine Trial in Kids

The University of Oxford has launched the first study to assess the safety and immune responses of its Covid-19 vaccine in children and young adults with first vaccinations expected

The University of Oxford has launched the first study to test COVID-19 vaccine safety in children and young adults. This trial will assess if children and young adults aged 6-17 years develop a good immune response with the ChAdOx1 nCoV-19 vaccine.

"While most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination," Andrew Pollard, Professor, and Chief Investigator on the Oxford vaccine trial, said in a statement.

COVID-19 in Children Mostly Less Severe
COVID-19 infection causes milder symptoms in children compared to adults. This makes them more resilient to the infection and also reduces their need for hospitalization.

‘The Oxford University begins COVID-19 vaccine trial for children.’

"These new trials will extend our understanding of control of SARS-CoV2 to younger age groups."

The study builds on previous trials of the vaccine, which have shown that it is safe, produces strong immune system responses and has high efficacy in adults.This new trial, a single-blind, randomised phase II trial, will involve 300 volunteers, with up to 240 of these volunteers receiving the ChAdOx1 nCoV-19 vaccine, the University of Oxford said on Friday.

The remainder will receive a control meningitis vaccine, which has been shown to be safe in children but is expected to produce similar reactions, such as a sore arm.

COVID-19 Surge in Children Reported in Belgium
Among children under the age of 10, the number of new coronavirus cases has more than doubled in one week in Belgium, a top health official said here.

"The Covid-19 pandemic has had a profound negative impact on the education, social development and emotional well-being of children and adolescents, beyond illness and rare severe disease presentations," said Rinn Song, Paediatrician and Clinician-Scientist, Oxford Vaccine Group.

"It is therefore important to collect data on the safety and the immune response to our coronavirus vaccine in these age groups, so that they could potentially benefit from inclusion in vaccination programs in the near future."

COVID-19 Could Reverse Downward Trend in Infant Deaths: UNICEF
A WHO survey revealed that 52% of countries reported disruptions in health services for sick children and 51% in malnutrition management services.

The trial is funded by the UK's National Institute for Health Research (NIHR) and drugmaker AstraZeneca.

AstraZeneca's Covid-19 vaccine, developed jointly with the University of Oxford, has been approved for emergency use in several countries. A version of the vaccine is also being used in India.

More Kids Possibly Infected with COVID-19
Number of children infected with the COVID-19 is far more extensive than what is currently reported, a hidden detail that could greatly underestimate the demand for health care systems and pediatric intensive care units (PICUs).

While the vaccine remains effective against the original virus and at least one variant, first discovered in Kent, England, preliminary findings in a small-scale trial prompted South Africa to limit its use while it ascertains its efficacy against the variant that emerged there.

AstraZeneca had said it could take between six to nine months to produce Covid-19 vaccines that are effective against new variants of the virus.

Source-IANS